BillionToOne Inc.
BLLN | NASDAQ
$113.32
-$1.52 (-1.32%)
At close: Oct 30, 2026, 4:00 PM ET
$114.99
+$1.67 (+1.47%)
Pre-market:
Nov 2, 2026, 7:16 AM ET
Company Profile
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Key Executives
| Name | Position |
|---|---|
| Oguzhan Atay | Co-Founder, Chairman & Chief Executive Officer |
| David Tsao | Co-Founder, President, Chief Technology Officer & Director |
| Ross Taylor Jr. | Chief Financial Officer |
| Jaclyn | Vice President of Marketing |
| Jean Hayden | Vice President of Business Operations & Chief of Staff |
| John D. Lister | Chief Administrative Officer |
| Nancy Johnson | Senior Vice President of Sales & Commercial Operations |
| Shan Riku Sakakibara | Chief Product Officer |
| Thomas Lynch | Chief Compliance Officer, General Counsel & Secretary |
| Vaghar Haghiri | Senior Director of People Operations |
BillionToOne Inc.
| Country | United States |
| IPO Date | Nov 6, 2025 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 713 |
| CEO | Oguzhan Atay |
Contact Details
1035 O’Brien Drive Menlo Park,
California 94025 United States
Stock Details
| Ticker Symbol | BLLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002070849 |
| CUSIP Number | 090168105 |
| ISIN Number | US0901681058 |
| SIC Code | 8071 |
Recent News
- 3 days ago / seekingalpha.comBillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share
- 5 days ago / zacks.comBillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth
- 6 days ago / globenewswire.comBillionToOne to Participate in Two Upcoming Investor Conferences
- 19 days ago / globenewswire.comBillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
- 21 days ago / seekingalpha.comBillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials
- 26 days ago / globenewswire.comBillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
- 1 month ago / fool.comBillionToOne SVP Sells 1,416 Shares
- 2 months ago / fool.comBillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million
- 2 months ago / prnewswire.comBillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
- 2 months ago / prnewswire.comBillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
Add to Watchlist
Select watchlists to add or remove BLLN